174 related articles for article (PubMed ID: 10146897)
1. Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy.
Ballatori E; Roila F; Berto P; De Angelis V; Neri C; Olivieri A; Tonato M; Del Favero A
Pharmacoeconomics; 1994 Mar; 5(3):227-37. PubMed ID: 10146897
[TBL] [Abstract][Full Text] [Related]
2. Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. The Italian Group for Antiemetic Research.
J Clin Oncol; 1993 Dec; 11(12):2396-404. PubMed ID: 8246029
[TBL] [Abstract][Full Text] [Related]
3. Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research.
Support Care Cancer; 1994 May; 2(3):167-70. PubMed ID: 8032702
[TBL] [Abstract][Full Text] [Related]
4. Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.
Plosker GL; Milne RJ
Pharmacoeconomics; 1992 Oct; 2(4):285-304. PubMed ID: 10147044
[TBL] [Abstract][Full Text] [Related]
5. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research.
Lancet; 1992 Jul; 340(8811):96-9. PubMed ID: 1352024
[TBL] [Abstract][Full Text] [Related]
6. Ondansetron plus dexamethasone compared to the 'standard' metoclopramide combination.
Roila F
Oncology; 1993; 50(3):163-7. PubMed ID: 8459986
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of antiemetic therapy for ambulatory surgery.
Watcha MF; Smith I
J Clin Anesth; 1994; 6(5):370-7. PubMed ID: 7986508
[TBL] [Abstract][Full Text] [Related]
8. Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis.
Bhatia A; Tripathi KD; Sharma M
Indian J Med Res; 2004 Sep; 120(3):183-93. PubMed ID: 15489556
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Italian Group for Antiemetic Research.
Ann Oncol; 1994 Sep; 5(7):585-9. PubMed ID: 7993832
[TBL] [Abstract][Full Text] [Related]
10. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
Bhatia A; Tripathi KD; Sharma M
Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464
[TBL] [Abstract][Full Text] [Related]
11. Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.
Markham A; Sorkin EM
Drugs; 1993 Jun; 45(6):931-952. PubMed ID: 7691500
[TBL] [Abstract][Full Text] [Related]
12. Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy.
Navari RM; Province WS; Perrine GM; Kilgore JR
Cancer; 1993 Jul; 72(2):583-6. PubMed ID: 8319191
[TBL] [Abstract][Full Text] [Related]
13. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of granisetron-based versus standard antiemetic regimens in low-emetogenic chemotherapy: a hospital-based perspective from Malaysia.
Keat CH; Ghani NA
Asian Pac J Cancer Prev; 2013; 14(12):7701-6. PubMed ID: 24460356
[TBL] [Abstract][Full Text] [Related]
15. Ondansetron and metoclopramide as second-line antiemetics in women with nausea and vomiting in pregnancy: the EMPOWER pilot factorial RCT.
Robson S; McParlin C; Mossop H; Lie M; Fernandez-Garcia C; Howel D; Graham R; Ternent L; Steel A; Goudie N; Nadeem A; Phillipson J; Shehmar M; Simpson N; Tuffnell D; Campbell I; Williams R; O'Hara ME; McColl E; Nelson-Piercy C
Health Technol Assess; 2021 Nov; 25(63):1-116. PubMed ID: 34782054
[TBL] [Abstract][Full Text] [Related]
16. Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy.
Stewart DJ; Dahrouge S; Coyle D; Evans WK
J Clin Oncol; 1999 Jan; 17(1):344-51. PubMed ID: 10458253
[TBL] [Abstract][Full Text] [Related]
17. Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis.
Manusirivithaya S; Chareoniam V; Isariyodom P; Sungsab D
J Med Assoc Thai; 2001 Jul; 84(7):966-72. PubMed ID: 11759977
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting.
Zbrozek AS; Cantor SB; Cardenas MP; Hill DP
Am J Hosp Pharm; 1994 Jun; 51(12):1555-63. PubMed ID: 8092156
[TBL] [Abstract][Full Text] [Related]
19. Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy.
Fanning J; Hilgers RD
Obstet Gynecol; 1994 Apr; 83(4):601-4. PubMed ID: 8134073
[TBL] [Abstract][Full Text] [Related]
20. Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study.
Gebbia V; Testa A; Cannata G; Gebbia N
Anticancer Drugs; 1996 Sep; 7(7):734-7. PubMed ID: 8949983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
